Compare SOTK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | MCRB |
|---|---|---|
| Founded | 1975 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 71.0M |
| IPO Year | 1995 | 2015 |
| Metric | SOTK | MCRB |
|---|---|---|
| Price | $5.17 | $4.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 52.4K | ★ 114.4K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | $789,000.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.23 | $5.00 |
| 52 Week High | $6.24 | $29.98 |
| Indicator | SOTK | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 32.27 |
| Support Level | $5.01 | N/A |
| Resistance Level | $5.72 | $9.53 |
| Average True Range (ATR) | 0.39 | 0.55 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 17.89 | 1.80 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.